TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort

Murray, L.; Sedo, A.; Scott, M.; McManus, D.; Sloan, J. M.; Hardie, L. J.; Forman, D.; Wild, C. P.
October 2006
Gut;Oct2006, Vol. 55 Issue 10, p1390
Academic Journal
Background and aims: Oesophageal adenocarcinoma frequently develops on a background of metaplastic Barrett's epithelium. The development of malignancy is accompanied by genetic alterations, which may be promising biomarkers of disease progression. Methods: A case control study was conducted nested within a large unselected population based cohort of Barrett's patients. Incident oesophageal malignancies and high grade dysplasias were identified. For each case up to five controls were matched on age, sex, and year of diagnosis. Biopsies from the time of diagnosis of Barrett's epithelium were stained immunohistochemically for TP53, cyclin D1, cyclooxygenase 2 (COX-2), and β-catenin proteins. Results: Twenty nine incident oesophageal malignancies and six cases of high grade dysplasia were identified. The odds of diffuse or intense TP53 staining were substantially elevated in biopsies from patients who developed oesophageal adenocarcinoma compared with controls (odds ratio (OR) 11.7 (95% confidence interval (CI) 1.93, 71.4)). This difference was also present when all cases were considered (OR 8.42 (95% CI 2.37, 30.0). Despite the association with TP53 staining, only 32.4% of cases had an initial biopsy showing diffuse/intense TP53 staining. There were no significant associations between cyclin D1, COX-2, or β-catenin staining and case control status. The OR for positive staining for both TP53 and COX-2 was markedly increased in cases compared with controls (OR 27.3 (95% CI 2.89, 257.0)) although only 15% of cases had positive staining for both markers. Conclusions: Immunohistochemical detection of TP53 expression is a biomarker of malignant progression in Barrett's oesophagus but sensitivity is too low to act as a criterion to inform endoscopic surveillance strategies. Additional biomarkers are required which when combined with TP53 will identify, with adequate sensitivity and specificity, Barrett's patients who are at risk of developing cancer.


Related Articles

  • p53 Protein Overexpression in Low Grade Dysplasia (LGD) in Barrett's Esophagus: Immunohistochemical Marker Predictive of Progression. Weston, Allan P.; Banerjee, Sushanta K.; Sharma, Prateek; Tran, Trang M.; Richards, Robert; Cherian, Rachel // American Journal of Gastroenterology;May2001, Vol. 96 Issue 5, p1355 

    OBJECTIVES: The presence of low grade dysplasia (LGD) within Barrett's esophagus (BE) has a multitude of ramifications. Identification of markers that could risk stratify LGD would be of great clinical benefit. We aimed to prospectively evaluate the prognosis of the immunohistochemical...

  • Short Segment Barrett's Esophagus: Clinical and Histological Features, Associated Endoscopic Findings, and Association with Gastric Intestinal Metaplasia. Weston, Allan P.; Krmpotich, Philip; Makdisi, Walid F.; Cherian, Rachel; Dixon, Anita; McGregor, Douglas H.; Banerjee, Sushanta K. // American Journal of Gastroenterology;May1996, Vol. 91 Issue 5, p981 

    Objectives: To prospectively determine the clinical features, associated esophageal endoscopic lesions, associated gastric intestinal metaplasia, and prevalence of dysplasia and adenocarcinoma of short segment Barrett's. Methods: All patients undergoing upper endoscopy over a 5-month period were...

  • Do 40% of Patients Resected for Barrett Esophagus With High-Grade Dysplasia Have Unsuspected Adenocarcinoma? Tschanz, Elizabeth R. // Archives of Pathology & Laboratory Medicine;Feb2005, Vol. 129 Issue 2, p177 

    Results of studies conducted in the last 2 decades suggest that the detection of high-grade dysplasia in patients with Barrett esophagus is the harbinger of a synchronous adenocarcinoma, which remains undetected even by rigorous biopsy protocols but is discovered during resection of the...

  • The Incidence of Adenocarcinoma and Dysplasia in Barrett's Esophagus. O'Connor, J. Barry; Falk, Gary W.; Richter, Joel E. // American Journal of Gastroenterology;Aug1999, Vol. 94 Issue 8, p2037 

    OBJECTIVE: The reported incidence of adenocarcinoma in Barren's esophagus is variable. The aim of this study was to determine the incidence of dysplasia and adenocarcinoma in a population of patients with Barrett's esophagus followed prospectively and to compare these findings with other series....

  • Cyclooxygenase-2 Expression in the Barrett's Metaplasia-Dysplasia-Adenocarcinoma Sequence. Morris, Clive D.; Armstrong, Gordon R.; Bigley, Graham; Green, Helen; Attwood, Stephen E. A. // American Journal of Gastroenterology;Apr2001, Vol. 96 Issue 4, p990 

    OBJECTIVE: Increased expression of the inducible cyclooxygenase 2 (COX-2) enzyme has been detected in esophageal and colonic adenocarcinoma, and intake of aspirin and non-steroidal anti-inflammatory drugs, known COX-2 inhibitors, have been associated with reduced tumor formation. Elevated COX-2...

  • p53 and Neoplastic Progression in Barrett's Esophagus. Reid, Brian J. // American Journal of Gastroenterology;May2001, Vol. 96 Issue 5, p1321 

    Introduces the article "p53 Protein Overexpression in Low Grade Dysplasia (LGD) in Barrett's Esophagus: Immunohistochemical Marker Predictive of Progression," by Allan P. Weston, Sushanta K. Banerjee, Prateek Sharma, Trang M. Tran, Robert Richards and Rachel Cherian.

  • p53 Expression in Endocervical and Endometrial Adenocarcinomas. McHugh, Mary; Bose, Shikha; Palazzo, Juan P. // International Journal of Surgical Pathology;Apr1995, Vol. 2 Issue 4, p269 

    The expression of monoclonal antibody p53 (PAb 1801) was studied by immunohistochemistry in 16 endocervical and 28 endometrial adenocarcinomas. Eight endocervical and 17 endometrial carcinomas were p53 positive. The nuclear staining varied from focal to diffuse strong positivity. Follow-up...

  • Role of the p53/p21 system in the response of human colon carcinoma cells to Doxorubicin. Ravizza, Raffaella; Gariboldi, Marzia B.; Passarelli, Laura; Monti, Elena // BMC Cancer;2004, Vol. 4, p92 

    Background: Colon adenocarcinomas are refractory to a number of widely used anticancer agents. Multifactorial mechanisms have been implicated in this intrinsically resistant phenotype, including deregulation of cell death pathways. In this regard, the p53 protein has a well established role in...

  • Surgical Treatment of Barrett's Esophagus: 1980-2003. Csendes, Attila // World Journal of Surgery;Mar2004, Vol. 28 Issue 3, p225 

    Barrett's esophagus is a complication of long-standing gastroesophageal reflux and can be a premalignant condition. The goals of surgical treatment, which were well summarized by DeMeester, have been increased and more detailed by us. They consist of (1) controlling symptoms of gastroesophageal...


Read the Article


Sign out of this library

Other Topics